Wealthy countries at the front of the queue for jabs are best placed to deal with storage challenges. Photo / 123RF
Lex COMMENT
It is not enough to manufacture a new vaccine on an unprecedented scale. Nor to break all development speed records. Covid-19 jabs, once approved, need to be distributed intact. Shipping is a logistical feat that could determine the market share of rivals Moderna and Pfizer.
German logistics giant
Deutsche Post DHL this week pointed out that two-thirds of the world's population would struggle to access any vaccine that had to be stored at freezing temperatures. US health officials last week also said the complexity of Pfizer's plan for vaccine storage would make it hard to deliver efficiently.
The issue is acute for a new type of vaccine that uses messenger RNA (mRNA) to trigger an immune response. To prevent degradation, the vaccine needs to be stored and distributed at very cold temperatures, making it hard to administer jabs in conventional settings such as pharmacies.
Moderna says its mRNA vaccine can now be stored at minus 20C. That may give it an edge over the mRNA vaccine being produced by Pfizer and Germany's BioNTech, which needs to be stored at minus 70C, though the US drugmaker says its temperature-controlled shipping containers solve some concerns.